Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor –Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Tissue

In precision oncology, reliable testing of predictive molecular biomarkers is the prerequisite for optimal patient treatment. Interlaboratory comparisons are a crucial tool to verify diagnostic performance and reproducibility of one's approach. Here, we describe the design and results of the first recurrent, internationally performed PIK3CA (phosphatidylinositol-4,5-bisphosphate 3 kinase catalytic subunit α) breast cancer tissue external quality assessment (EQA), which was organized by German Quality in Pathology GmbH and started in 2021.

Source: Journal of Molecular Diagnostics - April 30, 2024 Category: Pathology Authors: Carolin Schmidt, Robert St öhr, Lora Dimitrova, Matthias W. Beckmann, Matthias Rübner, Peter A. Fasching, Carsten Denkert, Ulrich Lehmann, Claudia Vollbrecht, Florian Haller, Arndt Hartmann, Ramona Erber Tags: Regular article Source Type: research